WHO ICTRP trial
An exploratory study on the efficacy and safety of lenvatinib combined with TACE…
ChiCTR2000035326 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000035326 |
|---|---|
| Public title | An exploratory study on the efficacy and safety of lenvatinib combined with TACE in neoadjuvant therapy for patients with locally advanced hepatocellular carcinoma |
| Scientific title | An exploratory study on the efficacy and safety of lenvatinib combined with TACE in neoadjuvant therapy for patients with locally advanced hepatocellular carcinoma |
| Primary sponsor | Zhongshan Hospital Fudan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Hepatocellular Carcinoma |
| Interventions | Single arm:Lenvatinib combined with TACE |
| Registration date | Aug 8, 2020 |
| Target size | Single arm:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: